Assesment of the Metabolomic Signature in COVID-19 Patients

Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)

NCT04497272•Centre Hospitalier Universitaire de Nice

Summary

Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•patient over 18 years of age
•affiliated to a social security scheme
•consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection
•confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture)
•Person subject to a guardianship order
•Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision

Locations (1)

CHU de nice

Nice, Alpes-Maritimes, France

Key Dates

Start Date

August 7, 2020

Primary Completion Date

March 1, 2021

Completion Date

July 31, 2022

Last Updated

August 31, 2022

Enrollment

150

ACTUAL participants

Conditions

COVID 19

Interventions

COVID-19 patients

OTHER

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

NCT07278388

PASC Post Acute Sequelae of COVID 19Fatigue

View study

RECRUITINGPHASE2

A Study to Examine Anktiva for the Treatment of COVID-19.

NCT07123727

Long COVIDLong COVID Syndrome+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assesment of the Metabolomic Signature in COVID-19 Patients

Inclusion Criteria

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

A Study to Examine Anktiva for the Treatment of COVID-19.

Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism